Compare Entegris Inc (ENTG) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Entegris Inc trades at $145.48 (market cap $23.39B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Entegris Inc is far larger — about 3.2× Spyre Therapeutics Inc. Common Stock's market cap, and Entegris Inc pays a 0.26% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ENTG | SYRE | |
|---|---|---|
Market Cap | $23.39B | $7.35B |
Volume | 2,918,074 | 1,624,631 |
Sector | Technology | Health |
52-Week High | $184.00 | $108.92 |
52-Week Low | $68.80 | $22.18 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $26.60B | $6.35B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $161.16, up 0.72% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results anticipated. Revenue remains stable around $3.2 billion, while profitability metrics show improvement, though valuation ratios like a P/E of 80.58 appear elevated. Positive sentiment is driven by AI-related semiconductor demand and recent institutional buying.
The outlook is positive given earnings momentum and sector tailwinds, but high valuation and competitive pressures pose risks. Upside to the $186.56 consensus price target depends on continued execution and market conditions.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
